Helseøkonomisk analyse av bevacizumab+paclitaxel sammenlignet med paclitaxel alene som førstelinjebehandling ved metastatisk brystkreft
Peer reviewed, Research report
MetadataShow full item record
Original versionRapport fra Kunnskapssenteret 5/2009
BACKGROUND The Norwegian Knowledge Centre for the Health Services has been commissioned by Norwegian Directorate of Health’s Cancer Programme to make an assessment of the cost per progression-free year gained associated with the use of bevacizumab in combination with paclitaxel versus paclitaxel alone, as first line treatment for metastatic breast cancer. The result is likely to have bearings on a possible revision of the treatment guidelines for breast cancer in Norway. METHODS We developed a health economic model of the Markov type in which we compared data from a clinical study, Miller et al. 2007, with Norwegian cost data associated with the treatment alternatives. RESULTS Mean progression-free time in the group treated with bevacizumab+paclitaxel was 1 1.2 years whereas it was 0.73 years in the comparator group. This resulted in an incremental effect of 0,47 progression-free years. With regard to quality of life, the incremental effect was 0.2 QALYs. We estimated the incremental costs associated with use of bevacizumab+paclitaxel from a health service perspective to be NOK 765 000, which translates into a cost per progression-free life year gained of NOK 1.6 million and a cost per QALY gained of NOK 3.8 million. The estimate from the societal perspective, where tax, value-added tax and social security payments were deducted, was approx. NOK 1.3 million per progression-free life-year and NOK 3 million per QALY gained. CONCLUSION The cost per progression-free year gained is relatively high, and the cost per QALY gained is higher than cost-effective thresholds which have been proposed in Norway.
PublisherNorwegian Knowledge Centre for the Health Services
Showing items related by title, author, creator and subject.
Sæterdal, Ingvil von Mehren; Juvet, Lene Kristine; Norderhaug, Inger Natvig (Rapport fra Kunnskapssenteret, Peer reviewed; Research report, 2008-01)3-PAGE EXECUTIVE SUMMARY Background Cervical cancer is the second most common cancer in women world-wide and affects about 300 women in Norway each year. Cervical cancer develops through cellular abnormalities in the ...
Juvet, Lene Kristine; Norderhaug, Inger Natvig (Rapport fra Kunnskapssenteret, Peer reviewed; Research report, 2008-02)SUMMARY IN ENGLISH IN THE REPORT. ********************************* Brystkreft og eggstokkreft er blant de hyppigste kreftformene som rammer kvinner i Norge. Man regner med at 5−10 % av disse krefttilfellene skyldes arv. ...
Vist, Gunn E.; Sæterdal, Ingvil; Johansen, Marit; Bergsaker, Marianne Riise; Hauge, Siri Helene; Fretheim, Atle (Rapport fra Kunnskapssenteret, Peer reviewed; Research report, 2009-05-20)BAKGRUNN: På oppdrag fra allmennpraktiker Ottar Grimstad ble vi bedt om å finne dokumentasjonsgrunnlaget for effekten av influensavaksinering av eldre og personer med kronisk sykdom. METODE: Vi søkte etter systematiske ...